Safety assessment of biotechnology-derived pharmaceutical products. General principles and the relevant cases.
Maki
E
E
Preclinical Development Dept., Janssen-Kyowa Co., Ltd., Tokyo, Japan.
D000818:Animals; D001709:Biotechnology; D016207:Cytokines / Q000235:genetics / Q000633:toxicity; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D006801:Humans; D011994:Recombinant Proteins / Q000633:toxicity*; D018570:Risk Assessment
D016207:Cytokines; D011994:Recombinant Proteins